Skip to content
Certified ManufacturersFor manufacturers

Sunrider Manufacturing, L.P.

Midlothian, TX, United States

Due-diligence report

Find an accredited testing lab and confirm its scope covers your product and methods.

Sunrider Manufacturing, L.P. is a dietary supplement manufacturer in Midlothian, TX, United States, certified to NSF/ANSI 455-2 GMP, with 1 manufacturing facility on NSF’s public NSF/ANSI 455 listing as of November 19, 2026. Listed dosage forms: capsules, liquids, powders, softgels and tablets.

Facilities listed
1
Last checked

Dosage forms

As listed in the product categories of this company’s NSF/ANSI 455-2 certified facilities.

Certified facilities

Manufacturing (1)

  • 3201 Challenger Drive, Midlothian, TX 76065, United States

    • Coating
    • Dry Formulation
    • Encapsulation
    • Liquid Formulation
    • Mixing
    • Packaging/Labeling Operation
    • Packaging/Labeling Operation - Primary Packaging
    • Packaging/Labeling Operation - Secondary Packaging
    • Quality Unit Operations
    • Tablet Compression
    • Warehousing

How Sunrider Manufacturing, L.P. compares

Among the 769 manufacturers we list, as of our last check.

FDA recall records

No food or dietary supplement recall found under the name Sunrider Manufacturing, L.P. in FDA’s enforcement reports, as of .

We match FDA records by company name only. A recall listed under a different name won’t appear here, and a different company with the same name could. FDA’s food enforcement records start in June 2012. How we check

FDA inspections

FDA lists 4 food or dietary supplement inspections at facilities matching Sunrider Manufacturing, L.P., from 2010 to 2025, as of . 1 found no objectionable conditions and 3 found conditions the firm was left to correct.

  • Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm

    Inspected

    Midlothian, Texas

    1 citation posted:

    • Specifications - finished dietary supplement (21 CFR 111.70(e))
    Full citation text
    • Specifications - finished dietary supplement (21 CFR 111.70(e))

      You did not establish product specifications for identity, purity, strength and composition.

    FEI 1000125398

  • Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm

    Inspected

    Midlothian, Texas

    14 citations posted:

    • Approve or reject procedures or specs (21 CFR 211.22(c))
    • Procedures not in writing, fully followed (21 CFR 211.22(d))
    • Training--operations, GMPs, written procedures (21 CFR 211.25(a))
    • Written procedures not established/followed (21 CFR 211.67(b))
    See all 14 citations
    • Approve or reject procedures or specs (21 CFR 211.22(c))

      The quality control unit lacks responsibility to reject all procedures or specifications impacting on the quality of drug products.

    • Procedures not in writing, fully followed (21 CFR 211.22(d))

      The responsibilities and procedures applicable to the quality control unit are not fully followed.

    • Training--operations, GMPs, written procedures (21 CFR 211.25(a))

      Employees are not given training in the particular operations they perform as part of their function.

    • Written procedures not established/followed (21 CFR 211.67(b))

      Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

    • Written calibration / inspection records not kept (21 CFR 211.68(a))

      Records of the inspections of automatic, mechanical or electronic equipment, including computers or related systems are not maintained.

    • Yield calculations not verified by 2nd person (21 CFR 211.103)

      Yield calculations are not performed by one person and independently verified by a second person.

    • Control procedures to monitor and validate performance (21 CFR 211.110(a))

      Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.

    • Deviations from laboratory control requirements (21 CFR 211.160(a))

      Deviations from written specifications are not justified.

    • Scientifically sound laboratory controls (21 CFR 211.160(b))

      Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

    • Lack of written stability program (21 CFR 211.166(a))

      There is no written testing program designed to assess the stability characteristics of drug products.

    • Records reviewed annually (21 CFR 211.180(e))

      Records are not maintained so that data therein can be reviewed at least annually to evaluate the quality standards of each drug product to determine the need for changes in specifications or manufacturing or control procedures.

    • No written record of investigation (21 CFR 211.192)

      Written records are not made of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications.

    • Testing Calculations (21 CFR 211.194(a)(5))

      Laboratory records are deficient in that they do not include all calculations performed during testing.

    • Complaint Handling Procedure (21 CFR 211.198(a))

      Procedures describing the handling of written and oral complaints related to drug products are not written or followed.

    FEI 1000125398

  • No action indicated · No objectionable conditions found

    Inspected

    Midlothian, Texas

    2 citations posted:

    • Investigations of discrepancies, failures (21 CFR 211.192)
    • Second person sign off (21 CFR 211.194(a)(8))
    Full citation text
    • Investigations of discrepancies, failures (21 CFR 211.192)

      There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

    • Second person sign off (21 CFR 211.194(a)(8))

      Laboratory records do not include the initials or signature of a second person showing that the original records have been reviewed for accuracy, completeness, and compliance with established standards.

    FEI 1000125398

  • Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm

    Inspected

    Midlothian, Texas

    8 citations posted:

    • Master manufacturing record - controls, procedures (21 CFR 111.205(b)(2))
    • Master manufacturing record theoretical and expected yield (21 CFR 111.210(f))
    • Records - available; FDA (21 CFR 111.610(a))
    • GMP Training Frequency (21 CFR 211.25(a))
    See all 8 citations
    • Master manufacturing record - controls, procedures (21 CFR 111.205(b)(2))

      Your master manufacturing record did not establish controls and procedures to ensure that each batch met specifications.

    • Master manufacturing record theoretical and expected yield (21 CFR 111.210(f))

      Your master manufacturing record did not include a statement of the theoretical yield for each point, step, or stage of the manufacturing process to ensure quality control and the expected yield of the finished dietary supplement.

    • Records - available; FDA (21 CFR 111.610(a))

      You did not have required records, or copies of such records, readily available during the retention period for inspection and copying by FDA when requested.

    • GMP Training Frequency (21 CFR 211.25(a))

      GMP training is not conducted on a continuing basis to assure that employees remain familiar with CGMP requirements applicable to them.

    • Reports of Analysis (Components) (21 CFR 211.84(d)(2))

      Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals.

    • Adequate number of batches on stability (21 CFR 211.166(b))

      An adequate number of batches of each drug product are not tested to determine an appropriate expiration date.

    • Items to cover on annual reviews (21 CFR 211.180(e)(2))

      Written procedures are not established for evaluations done at least annually and including provisions for a review of complaints, recalls, returned or salvaged drug products, and investigations conducted for each drug product.

    • Labeling control records including specimens or copies (21 CFR 211.188(b)(8))

      Batch production and control records do not include complete labeling control records, including specimens or copies of all labeling used for each batch of drug product produced.

    FEI 1000125398

We match FDA inspections to companies by facility ZIP code (or city outside the US) and company name, so an inspection filed under a different name won’t appear here. FDA publishes final classifications only, and holds some back while enforcement is pending. Posted citations may differ from FDA’s final findings. FDA Data Dashboard · How we check

What we checked, and what we didn’t

Confirmed from NSF’s public listing

Last checked

  • NSF/ANSI 455-2 GMP certification
  • 1 facility address
  • Dosage forms in the certified scope
  • Operations listed for each facility

Not verified by us

  • Minimum order quantity (MOQ): the smallest order they accept
  • Lead times and current capacity
  • Prices
  • Other certifications, like organic, kosher, halal or NSF Certified for Sport
  • Whether they’re taking new clients
  • Conditions inside the facility. We don’t visit or audit facilities.

Ask about these in your quote request. How we verify

Other capsule manufacturers in the United States

  1. NSF lists 5 capsule facilities, including one in Tempe, AZ

    Tempe, AZ, United States21stcenturyvitamins.com

    • Capsules
    • Gummies
    • Softgels
    • Tablets
    Operations:
    • Kitting
    • Coating
    • Tablet compression
    • Encapsulation
    NSF/ANSI 455-2checked Nov 19, 2026
  2. NSF lists a capsule facility in Centennial, CO

    Centennial, CO, United States5280smc.com

    • Capsules
    Operations:
    • Encapsulation
    • Dry formulation
    NSF/ANSI 455-2checked Nov 19, 2026
  3. NSF lists a capsule facility in Garden Grove, CA

    Garden Grove, CA, United Statespackaging.com

    • Capsules
    • Gummies
    • Powders
    • Softgels
    • Tablets
    NSF/ANSI 455-2checked Nov 19, 2026
  4. NSF lists a capsule facility in Ada, MI

    Ada, MI, United Statesamway.com

    • Capsules
    • Powders
    • Softgels
    • Tablets
    Operations:
    • Kitting
    • Coating
    • Tablet compression
    • Encapsulation
    • +1 more
    NSF/ANSI 455-2checked Nov 19, 2026
  5. NSF lists 2 capsule facilities, including one in Chandler, AZ

    Gilbert, AZ, United Statesadeptlifesciences.com

    • Capsules
    • Liquids
    • Powders
    • Tablets
    Operations:
    • Liquid formulation
    • Tablet compression
    • Encapsulation
    • Dry formulation
    NSF/ANSI 455-2checked Nov 19, 2026
  6. NSF lists a capsule facility in Congers, NY

    Congers, NY, United Statesadhhealth.com

    • Capsules
    • Oils
    • Powders
    • Tablets
    Operations:
    • Coating
    • Tablet compression
    • Encapsulation
    • Dry formulation
    NSF/ANSI 455-2checked Nov 19, 2026